CML-CP: augmenting Sokal risk scores with bone marrow parameters

Access to the full content of this site is available only to registered healthcare professionals. Register to read more

Takeaway

  • In patients with chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib (Gleevec), the incorporation of bone marrow (BM) parameters into Sokal risk scores improved prognostic capability for PFS in low- and intermediate-risk groups.
  • BM parameters did not improve pr...